{"nct_id":"NCT04895722","title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-05","start_date":"2021-06-25","start_date_type":"ACTUAL","primary_completion_date":"2025-05-21","primary_completion_date_type":"ACTUAL","completion_date":"2026-04-30","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["MRK"]}